PM Stock Analysis: Philip Morris International | NYSE
Tobacco | NYSE, USA | Market Cap: 302.828m USD | 12M Return: 28.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 960M
EPS Trend: 98.1%
Qual. Beats: 2
Rev. Trend: 99.9%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Philip Morris International Inc. is a U.S.-incorporated tobacco company that manufactures and sells traditional cigarettes alongside a growing portfolio of smoke-free products. Its smoke-free range spans heat-not-burn, e-vapor, and oral nicotine items marketed under the IQOS, VEEV, and ZYN brands, and it also sells consumer accessories and a line of wellness products. The company was incorporated in 1987, is headquartered in Stamford, Connecticut, and trades on the NYSE under the ticker PM, having gone public in March 2008 following its spin-off from Altria Group. Listed in the Consumer Staples sector and the Tobacco sub-industry, it is classified as a mega-cap stock, reflecting its position as one of the largest publicly traded tobacco companies globally.
- IQOS smoke-free products drive margin expansion globally
- ZYN oral nicotine fuels US growth post Swedish Match deal
- Emerging market cigarette volumes decline as consumers shift
- EU flavor bans and excise tax hikes pressure pricing power
- Strong dollar reduces reported revenue across international markets
| Net Income: 10.9b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA 4.98 > 1.0 |
| NWC/Revenue: -1.26% < 20% (prev -12.25%; Δ 10.99% < -1%) |
| CFO/TA 0.20 > 3% & CFO 13.9b > Net Income 10.9b |
| Net Debt (43.1b) to EBITDA (18.1b): 2.39 < 3 |
| Current Ratio: 0.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.56b) vs 12m ago 0.31% < -2% |
| Gross Margin: 67.51% > 18% (prev 66.44%; Δ 1.07% > 0.5%) |
| Asset Turnover: 62.21% > 50% (prev 57.01%; Δ 5.20% > 0%) |
| Interest Coverage Ratio: 10.37 > 6 (EBIT TTM 16.1b / Interest Expense TTM 1.55b) |
| A: -0.01 (Total Current Assets 26.0b - Total Current Liabilities 26.5b) / Total Assets 68.3b |
| B: 0.53 (Retained Earnings 36.1b / Total Assets 68.3b) |
| C: 0.23 (EBIT TTM 16.1b / Avg Total Assets 68.4b) |
| D: -0.11 (Book Value of Equity -8.58b / Total Liabilities 74.9b) |
| Altman-Z'' = 3.13 = A |
| DSRI: 1.01 (Receivables 6.47b/5.89b, Revenue 42.5b/39.1b) |
| GMI: 0.98 (GM 66.44% / 67.51%) |
| AQI: 0.92 (AQ_t 0.50 / AQ_t-1 0.54) |
| SGI: 1.09 (Revenue 42.5b / 39.1b) |
| TATA: -0.04 (NI 10.9b - CFO 13.9b) / TA 68.3b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of July 28, 2026, the stock is trading at USD 195.66 with a total of 2,598,219 shares traded. Over the past week, the price has changed by +1.53%, over one month by +6.99%, over three months by +22.61% and over the past year by +28.51%.
Current recommended Stop Loss: 183.90 (which is 6% or 2.1 ATR below the current price).
Philip Morris International has received a consensus analysts rating of 4.06. Therefore, it is recommended to buy PM.
- StrongBuy: 7
- Buy: 5
- Hold: 4
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 196.3 | 0.3% |
P/E Trailing = 26.6555
P/E Forward = 23.0415
P/S = 7.1198
P/B = 1318.6993
P/EG = 2.7116
Revenue TTM = 42.5b USD
EBIT TTM = 16.1b USD
EBITDA TTM = 18.1b USD
Long Term Debt = 45.1b USD (from longTermDebt, last fiscal year)
Short Term Debt = 6.75b USD (from shortTermDebt, last quarter)
Debt = 49.1b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 43.1b USD (calculated: Debt 49.1b - CCE 6.00b)
Enterprise Value = 346b USD (303b + Debt 49.1b - CCE 6.00b)
Interest Coverage Ratio = 10.37 (Ebit TTM 16.1b / Interest Expense TTM 1.55b)
EV/FCF = 27.99x (Enterprise Value 346b / FCF TTM 12.4b)
FCF Yield = 3.57% (FCF TTM 12.4b / Enterprise Value 346b)
FCF Margin = 29.05% (FCF TTM 12.4b / Revenue TTM 42.5b)
Net Margin = 25.56% (Net Income TTM 10.9b / Revenue TTM 42.5b)
Gross Margin = 67.51% ((Revenue TTM 42.5b - Cost of Revenue TTM 13.8b) / Revenue TTM)
Gross Margin QoQ = 68.43% (prev 68.06%)
Tobins Q-Ratio = 5.07 (Enterprise Value 346b / Total Assets 68.3b)
Interest Expense / Debt = 3.15% (Interest Expense 1.55b / Debt 49.1b)
Taxrate = 20.60% (3.06b / 14.8b)
NOPAT = 12.8b (EBIT 16.1b * (1 - 20.60%))
Current Ratio = 0.98 (Total Current Assets 26.0b / Total Current Liabilities 26.5b)
Debt / Equity = -5.72 (negative equity) (Debt 49.1b / totalStockholderEquity, last quarter -8.58b)
Debt / EBITDA = 2.39 (Net Debt 43.1b / EBITDA 18.1b)
Debt / FCF = 3.49 (Net Debt 43.1b / FCF TTM 12.4b)
Total Stockholder Equity = -9.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.90% (Net Income 10.9b / Total Assets 68.3b)
RoE = -112.2% (negative equity) (Net Income TTM 10.9b / Total Stockholder Equity -9.69b)
RoCE = 45.31% (EBIT 16.1b / Capital Employed (Equity -9.69b + L.T.Debt 45.1b))
RoIC = 27.51% (NOPAT 12.8b / Invested Capital 46.3b)
WACC = 4.70% (E(303b)/V(352b) * Re(5.06%) + D(49.1b)/V(352b) * Rd(3.15%) * (1-Tc(0.21)))
Discount Rate = 5.06% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 88.75 | Cagr: 0.22%
[DCF] Terminal Value 77.97% ; FCFF base≈11.0b ; Y1≈12.6b ; Y5≈18.6b
[DCF] Fair Price = 151.7 (EV 280b - Net Debt 43.1b = Equity 236b / Shares 1.56b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.06 | EPS CAGR: 12.34% | SUE: 3.32 | # QB: 2
Revenue Correlation: 99.85 | Revenue CAGR: 7.76% | SUE: 3.40 | # QB: 2
EPS current Quarter (2026-09-30): EPS=2.43 | Chg30d=-0.28% | Revisions=+17% | Analysts=12
EPS current Year (2026-12-31): EPS=8.39 | Chg30d=-0.38% | Revisions=-62% | GrowthEPS=+11.2% | GrowthRev=+6.7%
EPS next Year (2027-12-31): EPS=9.14 | Chg30d=+0.16% | Revisions=-62% | GrowthEPS=+9.0% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: -56% (up=2, down=11)